Classification Nuance. The OpenFDA dataset, which draws from the Structured Product Labeling (SPL) files, often includes multiple classification fields, and the specific string "Phosphate Binder [EPC]" may only be assigned to a single product. The other drugs are likely classified using: More Specific Classes: Many of those drugs (like sevelamer, ferric citrate, etc.) may be classified by their specific mechanism or chemical group, which also acts as a phosphate binder. Example: A drug might be classified as "Iron-Containing Compound [EPC]" or "Aluminum-Containing Compound [EPC]" instead of the more general "Phosphate Binder [EPC]". Different Classification Fields: The NDC data contains several classification fields. You might be checking the Established Pharmacological Class (pharm_class_epc), but the other drugs might be listed under: Mechanism of Action (pharm_class_moa), Physiological Effect (pharm_class_pe)
  Home  

Enter a class name or drug name above to search the database.

CD20-directed Cytolytic Antibody [EPC]

NDC Number Brand Name Generic Name Manufacturer Dosage Form DEA Sch. Marketing Start Date
0069-0238 Ruxience rituximab-pvvr Pfizer Laboratories Div Pfizer Inc INJECTION, SOLUTION 2020-01-23
0069-0249 Ruxience rituximab-pvvr Pfizer Laboratories Div Pfizer Inc INJECTION, SOLUTION 2020-01-23
0078-0669 ARZERRA ofatumumab Novartis Pharmaceuticals Corporation INJECTION, SOLUTION 2016-02-01
0078-0690 ARZERRA ofatumumab Novartis Pharmaceuticals Corporation INJECTION, SOLUTION 2016-02-01
0078-1007 KESIMPTA ofatumumab Novartis Pharmaceuticals Corporation INJECTION, SOLUTION 2009-10-26
50242-051 Rituxan rituximab Genentech, Inc. INJECTION, SOLUTION 1997-11-26
50242-053 Rituxan rituximab Genentech, Inc. INJECTION, SOLUTION 1997-11-26
50242-070 Gazyva obinutuzumab Genentech, Inc. INJECTION, SOLUTION, CONCENTRATE 2013-11-01
50242-108 Rituxan Hycela rituximab and hyaluronidase Genentech, Inc. INJECTION, SOLUTION 2017-06-22
50242-109 Rituxan Hycela rituximab and hyaluronidase Genentech, Inc. INJECTION, SOLUTION 2017-06-22
50242-150 OCREVUS ocrelizumab Genentech, Inc. INJECTION 2017-03-28
50242-554 Ocrevus Zunovo ocrelizumab and hyaluronidase Genentech, Inc. INJECTION, SOLUTION 2024-09-13
55513-224 Riabni rituximab-arrx Amgen, Inc INJECTION, SOLUTION 2021-01-06
55513-326 Riabni rituximab-arrx Amgen, Inc INJECTION, SOLUTION 2021-01-06
63459-103 Truxima rituximab-abbs Cephalon, Inc. INJECTION, SOLUTION 2020-05-04
63459-104 Truxima rituximab-abbs Cephalon, Inc. INJECTION, SOLUTION 2020-05-04
73150-150 BRIUMVI ublituximab TG Therapeutics, Inc. INJECTION, SOLUTION, CONCENTRATE 2022-12-28



 [EPC] Established Pharmacological Classification 

Loading full table content...